Affordable Access

A lazaroid mitigates postresuscitation myocardial dysfunction.

Authors
Type
Published Article
Journal
Critical Care Medicine
0090-3493
Publisher
Ovid Technologies (Wolters Kluwer) - Lippincott Williams & Wilkins
Publication Date
Volume
32
Issue
2
Pages
553–558
Identifiers
PMID: 14758178
Source
Medline
License
Unknown

Abstract

The lazaroid compound U-74389G, administered during cardiac arrest, mitigated postresuscitation myocardial dysfunction and improved survival.

Statistics

Seen <100 times